Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Excellent balance sheet with limited growth.
Share Price & News
How has Xenon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Price Volatility Vs. Market
How volatile is Xenon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
1 month ago | Simply Wall StNew Forecasts: Here's What Analysts Think The Future Holds For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
2 months ago | Simply Wall StDo Directors Own Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares?
Is Xenon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Price To Earnings Ratio
Price to Earnings Growth Ratio
Price to Book Ratio
How is Xenon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings per Share Growth Forecasts
Future Return on Equity
How has Xenon Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Return on Equity
How is Xenon Pharmaceuticals's financial position?
Financial Position Analysis
Debt to Equity History and Analysis
What is Xenon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Stability and Growth of Payments
Current Payout to Shareholders
Future Payout to Shareholders
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon Pimstone (52yo)
Dr. Simon N. Pimstone, M.B. ChB., Ph.D., FRCPC, M.D, is a Scientific Co-Founder of Xenon Pharmaceuticals Inc. in 1996 and has been its Chief Executive Officer since January 2003. He had served as President ...
CEO Compensation Analysis
|CEO & Director||17.5yrs||US$2.61m||0.78% $3.6m|
|Chief Medical Officer||2.33yrs||US$1.07m||0.13% $590.6k|
|Vice President of Corporate Affairs & Investor Relations||3.33yrs||no data||no data|
|Senior Vice President of Human Resources||0.83yr||no data||no data|
|Executive Vice President of Strategy & Innovation||no data||US$552.84k||0.048% $223.5k|
|Senior Vice President of Drug Discovery||4.42yrs||US$545.00k||no data|
|CEO & Director||17.5yrs||US$2.61m||0.78% $3.6m|
|Independent Director||16.75yrs||US$142.11k||0.17% $807.2k|
|Independent Director||21.33yrs||US$147.38k||0.35% $1.6m|
|Independent Chairman||21.17yrs||US$169.62k||0.20% $927.9k|
|Independent Director||23.67yrs||US$131.93k||0.78% $3.6m|
|Independent Director||16.5yrs||US$144.74k||0.097% $452.8k|
|Independent Director||0.50yr||no data||no data|
|Independent Director||5.17yrs||US$139.84k||0.043% $199.7k|
|Independent Director||3.83yrs||US$136.08k||0.34% $1.6m|
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Recent Insider Transactions
Xenon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Xenon Pharmaceuticals Inc.
- Ticker: XENE
- Exchange: NasdaqGM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$465.506m
- Shares outstanding: 34.97m
- Website: https://www.xenon-pharma.com
Number of Employees
- Xenon Pharmaceuticals Inc.
- 200 – 3650 Gilmore Way
- British Columbia
- V5G 4W8
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XENE||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Nov 2014|
|XP0||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2014|
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company’s product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/10 00:02|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.